The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions.
The effects of the potassium channel opener levcromakalim (BRL 38227) 7.5 micrograms kg-1 were examined on urodynamic variables and blood pressure during inflow and voiding cystometry in six high spinal cord lesion patients. Levcromakalim administration significantly increased the duration of bladder contraction (197 +/- 128 s to 267 +/- 167 s, P < 0.05) and also reduced blood pressure (126 +/- 13/67 +/- 9 mm Hg to 104 +/- 25/52 +/- 12 mm Hg) but was without effect on other urodynamic parameters. Because of concerns about hypotensive responses, further studies involving higher doses of levcromakalim should be considered only if the drug was administered intravesically.
Komersova
K
K
Department of Clinical Pharmacology and Therapeutics, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Rogerson
J W
JW
Conway
E L
EL
Lim
T C
TC
Brown
D J
DJ
Krum
H
H
Jackman
G P
GP
Murdoch
R
R
Louis
W J
WJ
D000328:Adult; D000704:Analysis of Variance; D001578:Benzopyrans / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D019806:Cromakalim; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology*; D013119:Spinal Cord Injuries / Q000503:physiopathology*; D001750:Urinary Bladder, Neurogenic / Q000503:physiopathology*; D014563:Urodynamics / Q000187:drug effects*
D001578:Benzopyrans; D015221:Potassium Channels; D011758:Pyrroles; D019806:Cromakalim